Zacks Investment Research lowered shares of Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) from a buy rating to a hold rating in a report released on Thursday.
According to Zacks, “Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. “
Other equities research analysts also recently issued research reports about the stock. ValuEngine raised shares of Threshold Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, August 3rd. Stifel Nicolaus reaffirmed a hold rating and set a $0.40 price objective on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. They set a buy rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Threshold Pharmaceuticals has a consensus rating of Hold and an average target price of $5.37.
Threshold Pharmaceuticals (NASDAQ:MTEM) opened at 6.32 on Thursday. The firm has a 50-day moving average of $5.63 and a 200 day moving average of $5.59. Threshold Pharmaceuticals has a 1-year low of $3.85 and a 1-year high of $14.52. The firm’s market cap is $169.89 million.
Threshold Pharmaceuticals (NASDAQ:MTEM) last released its earnings results on Monday, July 31st. The biotechnology company reported $0.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.99. The company had revenue of $3.00 million during the quarter. On average, analysts predict that Threshold Pharmaceuticals will post ($1.32) EPS for the current year.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.